266 related articles for article (PubMed ID: 21045158)
1. Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.
Shultz JC; Goehe RW; Wijesinghe DS; Murudkar C; Hawkins AJ; Shay JW; Minna JD; Chalfant CE
Cancer Res; 2010 Nov; 70(22):9185-96. PubMed ID: 21045158
[TBL] [Abstract][Full Text] [Related]
2. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
3. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
5. SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.
Shultz JC; Goehe RW; Murudkar CS; Wijesinghe DS; Mayton EK; Massiello A; Hawkins AJ; Mukerjee P; Pinkerman RL; Park MA; Chalfant CE
Mol Cancer Res; 2011 Jul; 9(7):889-900. PubMed ID: 21622622
[TBL] [Abstract][Full Text] [Related]
6. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
7. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
8. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
[TBL] [Abstract][Full Text] [Related]
9. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
[TBL] [Abstract][Full Text] [Related]
10. hnRNP U enhances caspase-9 splicing and is modulated by AKT-dependent phosphorylation of hnRNP L.
Vu NT; Park MA; Shultz JC; Goehe RW; Hoeferlin LA; Shultz MD; Smith SA; Lynch KW; Chalfant CE
J Biol Chem; 2013 Mar; 288(12):8575-8584. PubMed ID: 23396972
[TBL] [Abstract][Full Text] [Related]
11. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y
Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
14. SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness.
Massiello A; Chalfant CE
J Lipid Res; 2006 May; 47(5):892-7. PubMed ID: 16505493
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
[TBL] [Abstract][Full Text] [Related]
16. The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
Porcelli L; Giovannetti E; Assaraf YG; Jansen G; Scheffer GL; Kathman I; Azzariti A; Paradiso A; Peters GJ
Curr Drug Targets; 2014; 15(14):1322-30. PubMed ID: 25479544
[TBL] [Abstract][Full Text] [Related]
17. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40.
Patel NA; Kaneko S; Apostolatos HS; Bae SS; Watson JE; Davidowitz K; Chappell DS; Birnbaum MJ; Cheng JQ; Cooper DR
J Biol Chem; 2005 Apr; 280(14):14302-9. PubMed ID: 15684423
[TBL] [Abstract][Full Text] [Related]
18. RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Xu ZH; Hang JB; Hu JA; Gao BL
Int J Clin Exp Pathol; 2013; 6(8):1493-504. PubMed ID: 23923067
[TBL] [Abstract][Full Text] [Related]
19. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
20. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells.
Eisenreich A; Malz R; Pepke W; Ayral Y; Poller W; Schultheiss HP; Rauch U
Circ J; 2009 Sep; 73(9):1746-52. PubMed ID: 19597299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
